Sign In
Buy COLL
$31.06
+0.580 (+1.90%)
At Close: Jun 03, 2026
Collegium Pharmaceutical: Stock Deserves A "Buy" Call On Undervaluation Of ADHD Drug
02:53pm, Monday, 30'th Jun 2025
Collegium is shifting focus from opioids to ADHD with Jornay PM, which is showing strong prescription growth and could become a blockbuster product. The company is undervalued relative to peers, with
Collegium to Participate in Upcoming Investor Conferences
04:01pm, Monday, 19'th May 2025
STOUGHTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences:
Collegium Announces $25 Million Accelerated Share Repurchase Program
08:05am, Monday, 12'th May 2025
STOUGHTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified biopharmaceutical company committed to improving the lives of people living wi
Collegium Pharmaceutical, Inc. (COLL) Q1 2025 Earnings Call Transcript
02:04am, Friday, 09'th May 2025
Call Start: 16:30 January 1, 0000 5:05 PM ET Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q1 2025 Earnings Call May 8, 2025 16:30 ET Company Participants Ian Karp - Head, Investor Relations Vikram Ka
Compared to Estimates, Collegium Pharmaceutical (COLL) Q1 Earnings: A Look at Key Metrics
06:31pm, Thursday, 08'th May 2025
The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wal
Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Surpass Estimates
06:20pm, Thursday, 08'th May 2025
Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.49 per share, beating the Zacks Consensus Estimate of $1.43 per share. This compares to earnings of $1.45 per share a year ago.
Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress
04:01pm, Thursday, 08'th May 2025
– Generated Q1'25 Quarterly Net Revenue of $177.8 Million, Up 23% Year-over-Year – – Grew Jornay PM ® Prescriptions by 24% Year-over-Year and Reported Quarterly Net Revenue of $28.5 Million; Jo
Collegium Pharmaceutical (COLL) Expected to Beat Earnings Estimates: Should You Buy?
11:08am, Thursday, 01'st May 2025
Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Collegium to Report First Quarter 2025 Financial Results on May 8, 2025
08:00am, Thursday, 24'th Apr 2025
STOUGHTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report first quarter 2025 financial results after the market closes on�
Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now?
10:45am, Wednesday, 23'rd Apr 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference
08:00am, Tuesday, 01'st Apr 2025
STOUGHTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that management will participate in a fireside chat at the 24th Annual Needham Healt
Collegium to Present Real-World Data at PainConnect 2025, the American Academy of Pain Medicine's Annual Meeting
08:00am, Thursday, 27'th Mar 2025
STOUGHTON, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will present four posters highlighting real-world patient data from its differenti
Collegium Announces Updates to its Board of Directors and Executive Leadership Team
07:00am, Monday, 17'th Mar 2025
– Gino Santini Appointed as Chairman of the Board, Michael Heffernan, Founder and Chairman and Gwen A. Melincoff, Board Member to Retire from Board –
STOUGHTON, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will have two poster presentations highlighting real-world data from its different
Collegium Pharmaceutical's Shareholders Might Be In For A Pain-Free 2025
04:07am, Sunday, 09'th Mar 2025
Collegium Pharmaceutical Inc. is a specialty pharma company with strong cash flow, high EBITDA margins, and a focus on non-abusive painkillers and ADHD drugs. The new CEO has a proven track record, pr
